Literature DB >> 19079073

Promise of mGluR2/3 activators in psychiatry.

P Jeffrey Conn1, Carrie K Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19079073      PMCID： PMC2907744          DOI： 10.1038/npp.2008.156

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  6 in total

1.  Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine.

Authors:  Michael P Johnson; Melvyn Baez; G Erik Jagdmann; Thomas C Britton; Thomas H Large; David O Callagaro; Joseph P Tizzano; James A Monn; Darryle D Schoepp
Journal:  J Med Chem       Date:  2003-07-17       Impact factor: 7.446

Review 2.  Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.

Authors:  Chad J Swanson; Mark Bures; Michael P Johnson; Anni-Maija Linden; James A Monn; Darryle D Schoepp
Journal:  Nat Rev Drug Discov       Date:  2005-02       Impact factor: 84.694

3.  Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.

Authors:  Ruggero Galici; Carrie K Jones; Kamondanai Hemstapat; Yi Nong; Nicholas G Echemendia; Lilly C Williams; Tomas de Paulis; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2006-04-11       Impact factor: 4.030

4.  A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.

Authors:  Ruggero Galici; Nicholas G Echemendia; Alice L Rodriguez; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2005-08-25       Impact factor: 4.030

5.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.

Authors:  Sandeep T Patil; Lu Zhang; Ferenc Martenyi; Stephen L Lowe; Kimberley A Jackson; Boris V Andreev; Alla S Avedisova; Leonid M Bardenstein; Issak Y Gurovich; Margarita A Morozova; Sergey N Mosolov; Nikolai G Neznanov; Alexander M Reznik; Anatoly B Smulevich; Vladimir A Tochilov; Bryan G Johnson; James A Monn; Darryle D Schoepp
Journal:  Nat Med       Date:  2007-09-02       Impact factor: 53.440

Review 6.  Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?

Authors:  Darryle D Schoepp DD; Gerard J Marek
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-04
  6 in total
  16 in total

1.  Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists.

Authors:  José L Moreno; Terrell Holloway; Laura Albizu; Stuart C Sealfon; Javier González-Maeso
Journal:  Neurosci Lett       Date:  2011-01-27       Impact factor: 3.046

Review 2.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

Review 3.  Glutamatergic targets for new alcohol medications.

Authors:  Andrew Holmes; Rainer Spanagel; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2013-09-01       Impact factor: 4.530

4.  Genetic, pharmacological and lesion analyses reveal a selective role for corticohippocampal GLUN2B in a novel repeated swim stress paradigm.

Authors:  C Kiselycznyk; P Svenningsson; E Delpire; A Holmes
Journal:  Neuroscience       Date:  2011-06-23       Impact factor: 3.590

Review 5.  Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction.

Authors:  Alan J Cross; Robert Anthenelli; Xia Li
Journal:  Biol Psychiatry       Date:  2017-11-21       Impact factor: 13.382

6.  Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.

Authors:  Adam L Halberstadt; Jochem V F van der Zee; Muhammad Chatha; Mark A Geyer; Susan B Powell
Journal:  Psychopharmacology (Berl)       Date:  2018-11-17       Impact factor: 4.530

7.  Metabotropic Glutamate Receptors: MODULATORS OF CONTEXT-DEPENDENT FEEDING BEHAVIOUR IN C. ELEGANS.

Authors:  James Dillon; Christopher J Franks; Caitriona Murray; Richard J Edwards; Fernando Calahorro; Takeshi Ishihara; Isao Katsura; Lindy Holden-Dye; Vincent O'Connor
Journal:  J Biol Chem       Date:  2015-04-13       Impact factor: 5.157

Review 8.  Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors.

Authors:  Branden J Stansley; P Jeffrey Conn
Journal:  Trends Pharmacol Sci       Date:  2019-02-26       Impact factor: 14.819

9.  Selective silencing of individual dendritic branches by an mGlu2-activated potassium conductance in dentate gyrus granule cells.

Authors:  János Brunner; Jeanne Ster; Susan Van-Weert; Tibor Andrási; Máté Neubrandt; Corrado Corti; Mauro Corsi; Francesco Ferraguti; Urs Gerber; János Szabadics
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

10.  Group II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons.

Authors:  Min-Juan Wang; Yan-Chun Li; Melissa A Snyder; Huaixing Wang; Feng Li; Wen-Jun Gao
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.